Le Lézard
Classified in: Health, Covid-19 virus
Subjects: CHI, DEI

Blue Cross Blue Shield of Massachusetts to Cover Pfizer/BioNTech COVID-19 Vaccines for Kids 5-11 at No Cost to Members

BOSTON, Oct. 28, 2021 /PRNewswire/ -- Blue Cross Blue Shield of Massachusetts (Blue Cross) today confirmed it will cover, with no cost share to members, the administration of Pfizer/BioNTech's Comirnaty® COVID-19 vaccine in children ages 5 to 11, pending authorization from the U.S. Food and Drug Administration (FDA) and in accordance with Centers for Disease Control (CDC) guidance. Comirnaty®, which is currently the only one of the three available COVID-19 vaccines in the U.S. to request emergency use authorization for use in young children, was fully approved by the FDA in August.

Blue Cross previously announced no-cost coverage for vaccines administered in other age groups and for approved third-dose booster shots.

The federal government has purchased the vaccines, which are being distributed free of charge, but clinicians and pharmacies can bill insurers for administration costs. Medicare covers vaccine administration for Medicare Advantage and Medex members when administered by any clinician who accepts Medicare.

"Vaccines have proven to be safe, effective and the best tools we have to protect us against COVID-19," said Dr. Sandhya Rao, chief medical officer at Blue Cross. "We're dedicated to making it easier for our members to get vaccinated and to continuing our support of widespread vaccination in our communities."

About Blue Cross Blue Shield of Massachusetts
Blue Cross Blue Shield of Massachusetts (bluecrossma.org) is a community-focused, tax-paying, not-for-profit health plan headquartered in Boston. We are committed to the relentless pursuit of quality, equitable and affordable health care with an unparalleled consumer experience. Consistent with our promise to always put our members first, we are rated among the nation's best health plans for member satisfaction and quality. Connect with us on FacebookTwitterYouTube, and LinkedIn.



SOURCE Blue Cross Blue Shield of Massachusetts

These press releases may also interest you

at 07:00
PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") , a clinical-stage psychedelics biotech company, is pleased to announce that the Japan Patent Office has issued Japanese Patent No. 6967532 for KETABETtm, a combination formulation of...

at 07:00
Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") a clinical stage pharmaceutical development company is pleased to announce that it has appointed Mr. James Kinley as the Company's Chief Financial Officer ("CFO"), effective December 1,...

at 06:50
Merck , known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the Japan Pharmaceuticals and Medical Devices Agency (PMDA) for the first-line treatment of patients with...

at 06:50
The "Global Oncolytic Virus Therapy Market Outlook 2028" report has been added to ResearchAndMarkets.com's offering. The market is anticipated to garner a revenue of around USD 1060 Million by the end of 2028, up from a revenue of close to USD 160...

at 06:50
BD (Becton, Dickinson and Company) , a leading global medical technology company, today issued the following statement regarding testing for the COVID-19 Omicron variant of concern....

at 06:35
ImmunoGen Inc. , a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced positive top-line data from the pivotal SORAYA trial evaluating the safety and efficacy of mirvetuximab soravtansine...

News published on 28 october 2021 at 09:15 and distributed by: